Group published“RIG-I-inducing Small Molecules Potently Inhibit HMA-resistant AML through Igniting the Overloaded dsRNA Arsenal”on《Advanced Science》

Xiao Shujun Awarded 2025 Postdoctoral Innovative Talent Support Program

The research group published in Fundamental Research in 2025, titled ‘p53 mutation associated diagnosis across cancer types, underlying hematological malignancy as an applicable cancer type to p53 rescue therapy’

The research team carried out team-building activities in 2025 focusing on “alleviating scientific research pressure and stimulating innovative thinking”

Research Direction 1: “From 0 to 1” Targeted Anticancer Protein

Background: In clinical oncology, there are about 80 approved small-molecule targeted drugs. Most of them target oncoproteins whereas none targets tumor suppressor (the below figure). Mechanistically, a oncoprotein-targeting drug just need to inhibit protein function, with the molecular mechanisms of how a small molecule binds and inhibits protein is clear and understandable. However, a tumor […]
Research direction-2: drugging ‘smooth’ proteins without druggable pockets

Background: Among the 568 established therapeutical anticancer targets (Martinez-Jimenez, Nat Rev Can, 2020, 20, 555-572), a small number of them are overlappingly drugged (29/568; ~5%) whereas the vast majority of them remain “undruggable” (539/569; ~95%; the below figure). Mechanistically, the most of the drugged targets are kinases because they have a deep and narrow pocket for small […]
Members of the research team had a party and dinner at Meilan Lake, Shanghai

The members of the research group and Yan Ni celebrated their birthdays together

Dinner at the 2022 New Year’s Eve

The Lantern Festival cerebration in lab
